International Society on Thrombosis and Haemostasis, Inc.
Abstract Submission Guidelines

Delegates who would like to present their work at the meeting, either orally or as a poster, are invited to submit an abstract for consideration by the Scientific Committee. 

Please find the full Abstract Submission Guidelines below.
Important Dates:
Abstract submission opens: December 1, 2014
Submission deadline: February 6, 2015, 08:00, CET Please note - deadline extension due to adverse weather conditions!

Late breaking clinical trials submission deadline: May 19, 2015, midnight, CET – please note that a preliminary abstract must be submitted by February 4
Notifications to submitters: By April 22, 2015
Abstracts received after the deadline will not be accepted!
Technical Requirements:
The internet abstract submission system works best with Internet Explorer 7.0 or higher or Mozilla Firefox 3.0 or higher.
Cookies and JavaScript need to be enabled.
Abstracts can only be submitted online via the abstract submission form that can be found in the section "abstracts” on the official ISTH 2015 congress website.

Abstracts sent by post or email will not be accepted. No exceptions will be made.

The content of the abstract must be related to one of the topics listed below. To ensure smooth scoring of papers, the topic of your work must be selected during the submission process.

Main Topics

1.       Acquired coagulation disorders/inhibitors

2.       ADAMTS13

3.       Angiogenesis/vasculogenesis

4.       Animal models

5.       Antiphospholipid syndrome

6.       Antiplatelet agents

7.       Arterial vascular disorders

8.       Atherosclerosis

9.       Blood coagulation tests

10.   Cancer and thrombosis/hemostasis

11.   Clinical prediction rules

12.   Factor VIII – Factor IX

13.   Coagulation factor V, X, II, XIII

14.   Contact system

15.   Disseminated intravascular coagulation

16.   Endothelium/vessel wall

17.   Fibrinogen/fibrin/D-dimer

18.   Fibrinolytic system

19.   Guidance and guidelines

20.   Hemophilia – clinical

21.   Heparin and heparinoids

22.   Heparin-induced thrombocytopenia (HIT)

23.   Immune thrombocytopenia (ITP)

24.   Inflammation

25.   Innate and acquired immunity

26.   Intravascular devices and intervention

27.   Management of bleeding

28.   Massive blood loss

29.   Megakaryocytes and thrombopoiesis

30.   Microparticles

31.   Myocardial infarction

32.   Natural anticoagulants

33.   Non-vitamin K antagonist oral anticoagulants

34.   Nurses and Allied Health

35.   Pediatric thrombosis and hemostasis

36.   Platelet activation/adhesion/aggregation

37.   Platelet disorders, inherited/acquired

38.   Platelet transfusion

39.   Platelets and cancer

40.   Post-thrombotic syndrome

41.   Rare bleeding disorders

42.   Regulation of coagulation and fibrinolysis

43.   Reproductive issues

44.   Risk factors venous thrombosis

45.   Regulation of gene expression in vascular cells

46.   Signal transduction

47.   Stroke

48.   Thrombophilia

49.   Tissue factor – Factor VII

50.   Transfusion

51.   TTP/thrombotic microangiopathies

52.   Vascular progenitor and stem cells

53.   Venous thromboembolism – diagnosis

54.   Venous thromboembolism – epidemiology

55.   Venous thromboembolism - therapy

56.   Vitamin K antagonists

57.   Von Willebrand disease

58.   Von Willebrand Factor


Late breaking clinical trials abstracts

Clinical trials, the results of which will be available after the abstract submission deadline, can be submitted as such on a regular abstract including title and methods, and mentioning that results will be submitted as soon as available, and presented at the meeting. The abstract should be submitted under the type selection "ISTH 2015 Late Breaking Clinical Trial". Depending upon the date of submission of the results, they may be included in the Abstracts CD Rom or on the website only. If the results obtained in the Late Breaking Clinical Trial are not submitted to the Congress Office by May 19, 2015 the corresponding abstract will be withdrawn. Please note that a preliminary abstract needs to be submitted by the February 4, 2015 deadline to be considered.

Overall Guidelines

  • Please be informed that the abstract submission for the ISTH 2015 is free of charge.
  • The abstract must address scientific questions, detail clinical observations, or contain primary scientific data.
  • Abstracts submitted for ISTH2015 are embargoed from the time of submission.  This means that the data in the abstract cannot be submitted to other meetings once submitted for the ISTH2015 meeting. Likewise, abstracts must contain original information, not submitted, published or presented elsewhere prior to submission.
  • The first / presenting author is responsible for ensuring that all authors have read the abstract and agreed to be co-authors.
  • The Scientific Committee retains the right to reject abstracts containing previously submitted or presented data as they see fit.
  • All research and studies in submitted abstracts that involve human subjects or experimental animals must comply with the Declaration of Helsinki.
  • In clinical studies, please state whether informed consent was obtained and whether the study was approved by a recognized medical ethics committee.
  • If off-label use of drugs was involved in the study, please state this clearly.
  • If the research included in your abstract was supported by a pharmaceutical or diagnostics company, you can indicate this when submitting your abstract.
  • Please indicate the funding agency of your work if applicable.
  • The abstract title and text may not contain trade names. The Scientific Committee reserves the right to replace trade names in accepted abstracts.
  • Do not slice results from the same study into multiple abstracts. The Scientific Committee reserves the right to reject abstracts when inappropriate slicing of data is suspected.
  • Similarly, do not submit a copy or close copy of an abstract under more than 1 topic. Abstracts that appear to be submitted multiple times under different topics will be rejected.
  • Abstracts should be submitted in clear English to allow the reviewers to focus on the scientific content of the abstract. Non-English speaking authors are encouraged to have their abstract checked for grammar and spelling.
  • The Scientific Committee assumes that all presenting authors have proficiency in English, thus are able to present and respond to questions. Otherwise authors are encouraged to choose poster presentation as a preference.
  • For standardization, the acceptable length of the abstract is a maximum of 2,000 characters including non-visible characters, such as spaces and line breaks. This does not include the author’s details, titles and keywords.
  • Abstracts can be saved in "Draft” status to be re-edited and modified until the submission deadline (February 4 2015, midnight CET). Therefore, the submitter will be required to create a user account.
  • Abstracts fulfilling all criteria can be saved in "Final Submission” status.
  • Only abstracts in "Final Submission” status will be regarded as successfully submitted and considered for the congress.
  • The submitted / draft abstracts cannot be edited after the submission deadline.
  • The abstract should be structured into the following sections:

o    Background

o    Aims

o    Methods

o    Results

o    Conclusion (or Conclusions)

o    Keywords: please choose four keywords.

o    Registration of co-authors: please fill out the family names, first names, institute, city, country and e-mail addresses of the co-authors.

o    Graphs, tables and pictures are not allowed

o    Do not include a table in the body text of your abstract

o    Conflict of interest: It is the intent of the ISTH to provide high-quality sessions focused on educational content that is free from commercial influence or bias. Thus the submitting author of an abstract is requested to declare any potential conflicts of interest for all authors during abstract submission.

  • Abbreviations should be defined.
  • The submission of an abstract constitutes a formal commitment by the submitting (presenting) author to present the abstract (if accepted) in the session and the time assigned by the Scientific Committee. Registration fees will not be waived.
  • The presenting author of the abstract must be registered for the meeting. In order to benefit from the Early Bird Fee, you must register by March 11, 2015.
  • The registration fees for the presenting author will not be waived.


Language setting of your keyboard

The keyboard configuration of computers in non-Western countries may cause problems with the printing of the abstracts when special non-Western characters are used. To avoid these problems the language setting of your computer should be changed. To do this select "Start" then Settings", then "Control Panel" and then choosing "Keyboard."

Once in this menu, set the language of your computer to English (United States) or US (International). Next, open MS Word (or the word processing software you are using) and set the font type to Arial.  In the preparation of your abstract, if you require certain special characters that are not available, (e.g. '±', '®', 'μ'), use the insert symbol feature (special characters). To do this, select Arial as the font (unicoded, if possible), then select the required character, and copy and paste the symbol into the text of the abstract. If a special character is still not available, describe the character, e.g. 'alpha’.

Browser font preference: Before submitting your abstract, select Unicode as the preferred font. If Unicode is not available, please select Western.

Young Investigator Award

The Young Investigators Awards are provided in the form of travel grants to medical trainees and young scientists and are intended to assist with expenses relating to their participation at the Congress. Travel grants, consisting of CAD 700 will be available only for investigators who are first author on an accepted abstract. Travel grants are specifically intended to support young investigators; therefore applicants should be younger than 35 of age as of June 25, 2015.  The Scientific Committee will decide, according to the scores of the abstracts, which investigator receives a travel grant. This will be announced to the first author by e-mail before April 30, 2015.

Application criteria
Authors wishing to be considered for a grant should be:

·         the first author of a submitted abstract

·         35 years or younger of age (for 2015: authors born after June 25, 1980)

How to apply for a Young Investigator Award

·         Tick the appropriate box at the online abstract submission site.

·         Fill in the relevant questionnaire

·         Only complete applications will be considered.

·         The deadline for travel grant applications, supporting documents and additional  information is February 4, 2015

To be eligible for the award, the recipient must attend the Meeting, and members of the ISTH will be given priority.


Reach the World Award

The International Society on Thrombosis and Haemostasis will award travel grants to clinicians and scientists from developing countries to help subsidize travel to the Congress (a copy of current passport showing country of residence will be required). Those that are presenter and first author of an abstract submitted to the Congress will be prioritized.

Please check the relevant box on the abstract submission form to indicate you wish to apply for this grant. For those not submitting abstracts, please apply to  and explain how this grant and congress will be of benefit in driving up standards of care for patients. To be eligible for the award, the recipient must attend the Congress.


Abstract review, selection and publication

General comments

·         An international panel of experts will review the abstracts.

·         Each abstract will be reviewed by 4-6 different experts.

·         Abstracts may be selected for

o   oral presentation

o   poster presentation

o   rejection

·         The first author will receive confirmation of acceptance for oral presentation, electronic poster presentation, or a notice of rejection, by April 22 via e-mail.

·         No revisions can be made after the abstract deadline.

·         There will be room for a very limited number of late breaking abstracts with a later deadline. The author still needs to submit a preliminary abstract by February 4 with sufficient information for the reviewers to understand the importance of the data. The author is required to select the Submission Type LATE BREAKING CLINICAL TRIAL. A final abstract has to be submitted to the Congress Secretariat by May 19, 2015.

·         The best scoring abstracts will be selected for oral presentation.

·         Authors of abstracts selected for oral presentation will be informed about the type and date of the session, and presentation guidelines will be provided.

·         Poster presenters will be informed about the date of the poster exhibition and will receive guidelines for their preparation and presentation.

·         All accepted abstracts will be published as addendum supplement to the Journal of Thrombosis and Haemostasis and will be made available on the congress website at the time of the meeting, and on a USB stick.


Withdrawal policy

If authors wish to withdraw their abstracts from presentation or publication they are requested to send a letter via e-mail to the Congress secretariat before April 1, 2015.

Withdrawn abstracts cannot be presented nor will these be published.


Procedure abstract review & selection

All abstracts submitted by February 4 will be reviewed by an international panel of experts (representing all subspecialties from a large number of countries). The authors assign their abstracts to one of 58 topics. Within 10 days after the closure of the abstract submission, the reviewers (a total of about 500 experts) are requested to read and score each abstract in their category based on scientific merit. The scoring system is a scale ranging from 1 to 10, with a qualitative explanation of each grade. Once all abstracts have been reviewed, the scores are normalized and averaged.

The highest scoring abstracts are considered in detail and the top abstracts are selected for oral presentations.



 Key Dates

March 11, 2015
Early Registration Deadline

June 15, 2015
Online Registration Deadline

June 20-25, 2015
ISTH 2015